GAM repurposes underperforming fund as new OEIC for Mark Hawtin

Will reflect Star Disruptive Growth fund

Kathleen Gallagher
clock • 2 min read

GAM Investments is revamping its £88.8m Global Diversified fund to an OEIC version of its GAM Disruptive Growth fund, run by Mark Hawtin.

The Diversified fund, run by Kevin Kruczynski, has returned 23.8% in the three years till 21 January, while the MSCI world has returned 51.1% and the IA Global sector is up 47%, according to FE fundinfo. From 31 January the fund's strategy and holdings will change to reflect the Irish-domiciled $842.2m Star Disruptive fund, which the group said they have seen "strong demand" for in the UK. While UK investors could invest in the Dublin UCITS fund it was not available as a UK domiciled fund.  Rob Bailey, head of UK distribution at GAM, said this was "the first of a series of enhancem...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot